Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

For investors seeking momentum, Virtus Biotech Clinical Trials ETF BBC is probably on the radar now. The fund just hit a 52-week high and jumped 213.9% from its 52-week low price of $14.16 per share.

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

Biotech ETFs offer diversified exposure to the sector, reducing investment risk. Investing in top biotech ETFs can be cost-effective due to their low expense ratios. Large biotech ETFs provide better ...

Sun, December 14, 2025 at 4:58 PM UTC As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look to opportunities to be had within ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million. The move marked a full exit from the position, which was previously ...